A Study to Evaluate Safety and Efficacy of BEY1107 in Combination With Capecitabine in Patients With Metastatic Colorectal Cancer

This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).

本研究为一项I/II期临床试验，旨在评估BEY1107联合卡培他滨在对标准治疗（standard of care，SoC）难治或不耐受的转移性结直肠癌患者中的最大耐受剂量、安全性与有效性。